BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

APAC-Originated Obesity Drugs in the Clinic, Beyond Semaglutide

Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide and tirzepatide set the bench...

November 02, 2026 | Analysis

Pretzel Therapeutics Secures UK Approval to Advance PX578 into Phase II Trial for Rare Mitochondrial Disease

Regulatory milestone follows U.S. FDA clearance of Investigational New Drug application in August 2026 Initiation of Phase 2 Trial in POLG-PMD (POLG Dis...

November 02, 2026 | News

Parse Biosciences and Nomic Bio Launch 100-Million-Cell Immune Dataset to Advance AI Drug Discovery

Parse Biosciences, a leading provider of scalable and publicly available single-cell sequencing technology, a subsidiary of QIAGEN, andNomic Bio, a leader ...

November 02, 2026 | News

Merck Opens €300 Million Bioprocessing Hub in South Korea to Strengthen APAC Supply Chain

Merck’s largest life science investment in Asia-Pacific to date expands regional manufacturing capacity Integrated digital systems suppo...

October 30, 2026 | News

Yuyu Pharma Champions ‘One Pipeline, Two Markets’ Strategy to Bridge Human and Animal Health

Yuyu Pharma (KRX: 000220) CEO Robert Wonsang Yu shared the company's vision for connecting human and animal health at BIOPLUS-INTERPHEX KOREA 2026 (BIX 202...

October 30, 2026 | News

Kelun-Biotech Secures China NMPA Review for Sac-TMT and Pembrolizumab Combination in First-Line Lung Cancer

This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen o...

October 29, 2026 | News

Lynk Pharmaceuticals Reports Sustained Phase III Efficacy of Zemprocitinib in Rheumatoid Arthritis Through Week 76

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

October 29, 2026 | News

Octant Secures FDA Orphan Drug Designation for OCT-980 to Treat Retinitis Pigmentosa

Octant, Inc. (“Octant”), a clinical-stage drug discovery company developing correctors for protein misfolding diseases, announced that th...

October 29, 2026 | News

17 APAC-Made Biosimilars Approved in the US or EU in 2026

Seventeen times in 2026, the US Food and Drug Administration or the European Commission cleared a biosimilar that was developed or made in Asia-Pacific. Ni...

October 28, 2026 | Analysis

MEPSGEN Launches NanoCalibur Mini to Accelerate Nanoparticle Formulation for Drug Discovery

Automated system enables rapid, reproducible formulation screening with minimal sample consumption Completes the NanoCalibur® Series (Mini, Lab, Pro...

October 28, 2026 | News

TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours

TJ-C64B is an internally developed CLDN6 × 4-1BB bispecific antibody for which TJ Biopharma retains global rights, and is among the leading pro...

October 28, 2026 | News

Innovent Seeks China Approval for Sintilimab and Nolgileucel Combination in Advanced Melanoma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

October 28, 2026 | News

EU Approves Daiichi Sankyo and AstraZeneca’s Enhertu for Early HER2-Positive Breast Cancer

Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive diseas...

October 28, 2026 | News

Orphan Drug Incentives in 9 APAC Markets, Compared

Every January, regulatory affairs teams across Asia-Pacific rebuild the same spreadsheet. Which markets will designate this asset as an orphan? Which will ...

October 27, 2026 | Analysis

Stay Connected